Top 10 HIV and Hepatitis Stories of 2017
For our last issue, HIVandHepatitis.com reviews some the year's major HIV, viral hepatitis, and related news highlights. As we enter 2018, antiretroviral treatment for HIV is about as good as it can get, use of PrEP for HIV prevention is expanding rapidly, and most people can be cured of hepatitis C with 2 or 3 months of well-tolerated therapy. But these advances are still not reaching everyone who needs them. The search for a functional cure for HIV, better treatments for hepatitis B, and m...
HIV/AIDS
HIVandHepatitis.com 2017 Conference Coverage
Article listings by topic for HIVandHepatitis.com conference coverage in 2017, i...
EACS 2017: Up to a Quarter of HIV-Negative Gay Men Attending 3 English Clinics Used PrEP in the Last Year
A prospective cohort study of gay men attending 3 clinics in southern England --...
Many Americans Still Get HIV Diagnosis Years After Infection, CDC Says
Many people with HIV in the United States are still being diagnosed with HIV lat...
CROI 2017: HIV's Milder Cousin May Be Less Mild than Previously Thought
The virulence of HIV-2 virulence may have been underestimated, and although prog...
Hepatitis B
AASLD 2017: Treatment that Interferes with Viral Assembly Shows Promise for Hepatitis B
JNJ-56136379, an experimental drug that interferes with assembly of the hepatiti...
U.S. Approves New Hepatitis B Vaccine as Public Health Agencies Update Guidelines
On November 9 the U.S. Food and Drug Administration(FDA) approved Heplisav-B, a ...
AASLD 2014: Hepatitis B Testing and Treatment Rates Are Low Among U.S. Veterans
Only 15% of U.S. veterans have been tested for hepatitis B virus (HBV) infection...
AASLD 2017: Daily Aspirin Linked to Lower Liver Cancer Risk for Hepatitis B Patients
People with hepatitis B virus (HBV) who took an aspirin a day -- often recommend...
Hepatitis C
AASLD 2017: More Work and Lower Drug Prices Needed to Eliminate Hepatitis C Worldwide
Eliminating hepatitis C virus (HCV) as a global public health concern is feasibl...
AASLD 2017: HCV Infections Are Rising Among HIV+ Gay Men In San Diego
Hepatitis C incidence is increasing among gay and bisexual men living with HIV i...
AASLD 2016: Birth Cohort Screening and Linkage to Hepatitis C Care Still Weak in U.S.
Grave weaknesses in hepatitis C virus (HCV) screening and linkage to care are st...
AASLD 2017: Curing Hepatitis C with DAAs Reduces Liver Cancer Risk
People who achieved a sustained virological response to hepatitis C treatment lo...
HIV/Hepatitis Coinfection
AIDS 2016: Ongoing Hepatitis B Virus Replication Raises Mortality for People with HIV
People with HIV and hepatitis B virus (HBV) coinfection have more than double th...
EACS 2017: Hepatitis C Halved among Spanish People with HIV Thanks to HCV Treatment
Spain is making dramatic progress towards eliminating hepatitis C among people l...
EASL 2015: Hepatitis B and C Coinfection Linked to Worse Fibrosis than Hepatitis B Alone
People coinfected with both hepatitis B virus (HBV) and hepatitis C virus (HCV) ...
MORE:
- DDW 2014: Outcomes in HBV/HCV Coinfected People Depend on Which Virus Dominates
- Adefovir plus Hepatitis C Therapy May Prevent HBV Reactivation in HBV-HCV Coinfected Patients
- ICAAC 2008: Another Study Confirms Hepatitis B Virus Suppresses Hepatitis C Virus Replication in HBV-HCV Coinfected Individuals
Other Health News
CROI 2017: Prednisone Reduces Risk of Developing TB-IRIS after Starting Antiretroviral Treatment
Prednisone reduces the risk of immune restoration inflammatory syndrome (IRIS) i...
EACS 2017: European AIDS Clinical Society Strengthens HPV Vaccination Advice
The European AIDS Clinical Society (EACS) has recommended human papillomavirus (...
IDWeek 2016: Rapid Emergence of Drug-Resistant Gonorrhea Seen in Ohio
Routine surveillance in southern Ohio has detected a steep increase in gonorrhea...
ICAAC 2014: Single Dose of Flu Drug Peramavir Looks Safe and Effective
A single dose of the investigational neuraminidase inhibitorperamavir (Rapivab) ...
CONFERENCE COVERAGE
Copyright © 2025 www.hivandhepatitis.com. All Rights Reserved. Designed by JoomlArt.com.
Joomla! is Free Software released under the GNU General Public License.
Web Design and Development by Bread and Roses Web Design